Molecular and cellular heterogeneity: the hallmark of glioblastoma.

There has been increasing awareness that glioblastoma, which may seem histopathologically similar across many tumors, actually represents a group of molecularly distinct tumors. Emerging evidence suggests that cells even within the same tumor exhibit wide-ranging molecular diversity. Parallel to the discoveries of molecular heterogeneity among tumors and their individual cells, intense investigation of the cellular biology of glioblastoma has revealed that not all cancer cells within a given tumor behave the same. The identification of a subpopulation of brain tumor cells termed "glioblastoma cancer stem cells" or "tumor-initiating cells" has implications for the management of glioblastoma. This focused review will therefore summarize emerging concepts on the molecular and cellular heterogeneity of glioblastoma and emphasize that we should begin to consider each individual glioblastoma to be an ensemble of molecularly distinct subclones that reflect a spectrum of dynamic cell states.

[1]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[2]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[3]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[4]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.

[5]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[6]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[7]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[8]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[9]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[10]  B. Rosen,et al.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. , 2013, The Journal of clinical investigation.

[11]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[12]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[13]  J. Stockman,et al.  A Network Model of a Cooperative Genetic Landscape in Brain Tumors , 2011 .

[14]  Serban Nacu,et al.  A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. , 2010, Cancer cell.

[15]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[16]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[17]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[18]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[19]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[20]  R. McLendon,et al.  Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.

[21]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[22]  Robert J Dempsey,et al.  Science Times , 2022 .

[23]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[24]  L. Ricci-Vitiani,et al.  Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.

[25]  A. Iavarone,et al.  Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. , 2012, Cancer cell.

[26]  J. Greenman,et al.  Genetic analysis of head and neck squamous cell carcinoma using comparative genomic hybridisation identifies specific aberrations associated with laryngeal origin. , 2007, Cancer letters.

[27]  J. C. Love,et al.  EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. , 2014, Cancer discovery.

[28]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[29]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[30]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[31]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[32]  D. Cahill,et al.  From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. , 2013, Neurosurgical focus.

[33]  David T. W. Jones,et al.  Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge , 2014, Nature Reviews Cancer.

[34]  D. Troost,et al.  Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas , 2004, Brain Research Reviews.

[35]  Simon Kasif,et al.  Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells , 2014, Cell.

[36]  S. Pastorino,et al.  Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.

[37]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[38]  J. Rich,et al.  Deadly teamwork: neural cancer stem cells and the tumor microenvironment. , 2011, Cell stem cell.

[39]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[40]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[41]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[42]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[43]  L. Morgan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2015, Neuro-oncology.

[44]  K. Aldape,et al.  A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.

[45]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[46]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  W. Cavenee,et al.  Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.

[48]  Rong Wang,et al.  Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.

[49]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[50]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[51]  C. Brennan.  Genomic Profiles of Glioma , 2011, Current neurology and neuroscience reports.

[52]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[53]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[54]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.

[55]  Lynda Chin,et al.  Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.

[56]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[57]  Jim McDermott,et al.  Harnessing our opportunity to make primary care sustainable. , 2011, The New England journal of medicine.

[58]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[59]  Howard A. Fine,et al.  Integration and analysis of genome-scale data from gliomas , 2011, Nature Reviews Neurology.

[60]  G. Reifenberger,et al.  Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010, Acta Neuropathologica.

[61]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[62]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[63]  S. Scherer,et al.  Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.

[64]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[65]  Joseph G Boyer,et al.  A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. , 2011, Biochemistry.

[66]  Webster K. Cavenee,et al.  Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.

[67]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[68]  C. Brennan,et al.  Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.

[69]  R. McLendon,et al.  Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.

[70]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[71]  Michael R Stratton,et al.  Genomics and the continuum of cancer care. , 2011, The New England journal of medicine.

[72]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[73]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.